Acute Effects of Estradiol Administration on Brain Function During Fear Learning
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: estradiol.
- Who it may be relevant to
- Registry conditions: PTSD and Trauma-related Symptoms, Cognitive Decline in Older Adults, Post Menopausal Women. Basic parameters: from 60 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Neuroimaging Study of Fear Learning: Effects of Estrogen
Overview
The goal of current study is to better understand how fear is processed in the brain and how these processes are influenced by cognition and hormones. This research will focus specifically on postmenopausal female adults, because age-related changes in cognition and declining estrogen levels may contribute to anxiety symptoms and PTSD risk later in life.
Interventions
- Drug estradiol
oral 2mg tablet of estradiol
Primary outcome measures
- Neural Response to Fear Conditioning Task [Time frame: single visit, approximately 4 hours after taking study drug]
Secondary outcome measures (2)
- Skin Conductance Response [Time frame: single visit, approximately 4 hours after taking study drug]
- Subjective Fear and Risk Ratings [Time frame: single visit, approximately 4 hours after taking study drug]
Eligibility criteria
Inclusion criteria
- post-menopausal
- normal or corrected-to-normal vision
- English speaking
- stable medication use (no changes in the past three months)
Exclusion criteria
- use of hormone therapy containing synthetic estrogen
- MRI contraindications (e.g., irremovable ferrous metal in body, claustrophobia)
- history of neurological disorder (including mild cognitive impairment) or moderate to severe traumatic brain injury
- use of antipsychotic, opiate, or mood stabilizer (i.e., lithium) medication
- history of blood clots/deep vein thrombosis, prior stroke or TIA, uncontrolled hypertension
- history of migraine with aura
- severe liver disease
- history of breast, endometrial, or ovarian cancer
- smoking >10 cigarettes/day
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Basic science
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07737613 · STUDY00008306